Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial
- Resource Type
- article
- Source
- Haematologica, Vol 102, Iss 2 (2017)
- Subject
Diseases of the blood and blood-forming organs RC633-647.5 - Language
- English
- ISSN
- 0390-6078
1592-8721